Taigen Biopharmaceuticals Holdings Ltd (4157) — Cash Flow Reinvestment Rate
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Cash Flow Reinvestment Rate of 0.93x as of March 2026, reinvesting NT$103.81 Million (capex NT$18.13 Million plus investments NT$-85.67 Million) from operating cash flow of NT$111.04 Million. See Taigen Biopharmaceuticals Holdings Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Taigen Biopharmaceuticals Holdings Ltd Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for Taigen Biopharmaceuticals Holdings Ltd across 3 annual periods. For the full cash flow conversion analysis, see Taigen Biopharmaceuticals Holdings Ltd (4157) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for Taigen Biopharmaceuticals Holdings Ltd (2021–2025)
Year-by-year capital reinvestment analysis for Taigen Biopharmaceuticals Holdings Ltd. See Taigen Biopharmaceuticals Holdings Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 2.99x | NT$62.64 Million | NT$20.93 Million | NT$4.50 Million | ▼ -59.4% |
| 2023 | 7.37x | NT$152.85 Million | NT$20.74 Million | NT$7.39 Million | ▲ +1396.0% |
| 2021 | 0.49x | NT$309.90 Million | NT$629.07 Million | NT$11.83 Million | — |